Rapport Therapeutics, Inc. 8-K

What Happened

• On January 7, 2026, Rapport Therapeutics, Inc. (RAPP) filed a Current Report on Form 8-K to disclose a corporate update: the company issued a press release announcing the accelerated initiation of its RAP‑219 program, an expansion of its epilepsy portfolio, and continued progress across its pipeline. The press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Press release dated January 7, 2026 titled “Rapport Therapeutics Announces Accelerated Initiation of RAP‑219 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline” (Exhibit 99.1).
• Updated corporate presentation posted to Rapport’s Investors page at www.rapportrx.com and filed as Exhibit 99.2.
• Form 8‑K was filed on January 7, 2026 and signed on the company’s behalf by CFO Troy Ingelzi.
• The presentation and press release are furnished/included with the 8‑K for investor and analyst review.

Why It Matters

• This filing signals near‑term program advancement (accelerated initiation of RAP‑219) and strategic focus on epilepsy, which are material operational updates investors use to assess the company’s development timeline and pipeline priorities. The posted investor presentation provides additional details management will use in meetings with analysts and investors.